Anti-IL-1RAP scFv-mSA-S19-TAT fusion carrier as a multifunctional platform for versatile delivery of biotinylated payloads to myeloid leukemia cells.
Bispecific fusion protein
Cell-penetrating peptide
Endosomal escape
Myeloid leukemia
Protein-based delivery vehicle
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 10 2024
23 10 2024
Historique:
received:
16
08
2024
accepted:
17
10
2024
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
24
10
2024
Statut:
epublish
Résumé
Acute myeloid leukemia (AML) is an aggressive blood cancer with frequently poor clinical outcomes. This heterogeneous malignancy encompasses genetically, molecularly, and even clinically different subgroups. This makes it difficult to develop therapeutic agents that are effective for all subtypes of the disease. Therefore, a selective, universal, and adaptable delivery platform capable of carrying various types of anti-neoplastic agents is an unmet requirement in this area. Two multifunctional fusion proteins were designed for the delivery of biotinylated cargoes to human myeloid leukemia cells by fusing an anti-IL-1RAP single-chain antibody with streptavidin (tetramer or monomer), a cell-penetrating peptide (CPP), and an endosomolytic peptide in a single biomacromolecule. The designed fusions were analyzed primarily in silico, and the biofunctionality of the selected fusion was fully characterized via several binding assays, hemolysis assay, confocal microscopy and cell cytotoxicity assay after production via the Escherichia coli (E. coli) system. The refolded protein exhibited desirable binding activity to leukemic cells, pure antigen and biotinylated BSA. Further analyses revealed efficient cellular uptake, endosomolytic activity, and nuclear penetration without any detectable cytotoxicity toward normal epithelial cells. The described platform seems to have great potential for targeted delivery of different therapeutics to malignant myeloid cells.
Identifiants
pubmed: 39443595
doi: 10.1038/s41598-024-76851-7
pii: 10.1038/s41598-024-76851-7
doi:
Substances chimiques
Single-Chain Antibodies
0
Recombinant Fusion Proteins
0
Cell-Penetrating Peptides
0
Streptavidin
9013-20-1
Drug Carriers
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25080Subventions
Organisme : Pasteur Institute of Iran
ID : BD-9365
Organisme : Iran National Science Foundation
ID : 96011491
Informations de copyright
© 2024. The Author(s).
Références
1 Deschler, B. & Lübbert, M. Acute myeloid leukemia: epidemiology and etiology. Cancer Interdiscip. Int. J. Am. Cancer Soc. 107, 2099–2107. https://doi.org/10.1002/cncr.22233 (2006).
doi: 10.1002/cncr.22233
Maksimovic, N. et al. Incidence and mortality patterns of Acute myeloid leukemia in Belgrade, Serbia (1999–2013). Med. 54, 5. https://doi.org/10.3390/medicina54010005 (2018).
doi: 10.3390/medicina54010005
Shallis, R. M., Wang, R., Davidoff, A., Ma, X. & Zeidan, A. M. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 36, 70–87. https://doi.org/10.1016/j.blre.2019.04.005 (2019).
doi: 10.1016/j.blre.2019.04.005
pubmed: 31101526
Southam, C. M., Craver, L. F., Dargeon, H. W. & Burchenal, J. H. A study of the natural history of acute leukemia with special reference to the duration of the disease and the occurrence of remissions. Cancer. 4, 39–59. https://doi.org/10.1002/1097-0142(195101)4 (1951). :1%3C39::AID-CNCR2820040105%3E3.0.CO;2-G.
doi: 10.1002/1097-0142(195101)4
pubmed: 14801771
Cheung, E. et al. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann. Hematol. 98, 541–559. https://doi.org/10.1200/JCO.2014.60.0890 (2019).
doi: 10.1200/JCO.2014.60.0890
pubmed: 30666431
Knapper, S. et al. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood. 108, 3262–3270. https://doi.org/10.1182/blood-2006-04-015560 (2006).
doi: 10.1182/blood-2006-04-015560
pubmed: 16857985
Barreto, I. V. et al. Leukemic stem cell: a mini-review on clinical perspectives. Front. Oncol. 12, 931050. https://doi.org/10.3389/fonc.2022.931050 (2022).
doi: 10.3389/fonc.2022.931050
pubmed: 35814466
pmcid: 9270022
Afessa, B. & Peters, S. G. in Semin. Respir. Crit. Care Med.. 297–309 (Thieme Medical Publishers, Inc).
Tettamanti, S., Pievani, A., Biondi, A., Dotti, G. & Serafini, M. Catch me if you can: how AML and its niche escape immunotherapy. Leuk. 36, 13–22. https://doi.org/10.1038/s41375-021-01350-x (2022).
doi: 10.1038/s41375-021-01350-x
Arpinati, M. & Curti, A. Immunotherapy in acute myeloid leukemia. Immunother. 6, 95–106. https://doi.org/10.2217/imt.13.152 (2014).
doi: 10.2217/imt.13.152
Reilly, A. et al. Immunologic consequences of chemotherapy for acute myeloid leukemia. J. Pediatr. Hematol. Oncol. 35, 46. https://doi.org/10.1097/MPH.0b013e318266c0c8 (2013).
doi: 10.1097/MPH.0b013e318266c0c8
pubmed: 23018569
pmcid: 3526680
Bochennek, K. et al. Infectious complications in children with acute myeloid leukemia: decreased mortality in multicenter trial AML-BFM 2004. Blood Cancer J. 6, e382–e382. https://doi.org/10.1038/bcj.2015.110 (2016).
doi: 10.1038/bcj.2015.110
pubmed: 26771808
pmcid: 4742627
Khaldoyanidi, S., Nagorsen, D., Stein, A., Ossenkoppele, G. & Subklewe, M. Immune biology of acute myeloid leukemia: implications for immunotherapy. J. Clin. Oncol. 39, 419. https://doi.org/10.1200%2FJCO.20.00475 (2021).
doi: 10.1200/JCO.20.00475
pubmed: 33434043
pmcid: 8078464
Kabel, A., Zamzami, F., Al-Talhi, M., Al-Dwila, K. & Hamza, R. Acute myeloid leukemia: a focus on risk factors, clinical presentation, diagnosis and possible lines of management. Cancer Res. Treat. 5, 62–67. https://doi.org/10.12691/jcrt-5-2-4 (2017).
doi: 10.12691/jcrt-5-2-4
Le Dieu, R. et al. Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts. Blood. 114, 3909–3916. https://doi.org/10.1182/blood-2009-02-206946 (2009).
doi: 10.1182/blood-2009-02-206946
pubmed: 19710498
pmcid: 2773481
Santos, F. et al. Severe necrotizing stomatitis and osteomyelitis after chemotherapy for acute leukaemia. Aust Dent. J. 54, 262–265. https://doi.org/10.1111/j.1834-7819.2009.01129.x (2009).
doi: 10.1111/j.1834-7819.2009.01129.x
pubmed: 19709116
Pimenta, D. B. et al. The bone marrow microenvironment mechanisms in acute myeloid leukemia. Front. Cell. Dev. Biol. 9, 764698. https://doi.org/10.3389/fcell.2021.764698 (2021).
doi: 10.3389/fcell.2021.764698
pubmed: 34869355
pmcid: 8639599
Isidori, A. et al. The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment. Expert Rev. Hematol. 7, 807–818. https://doi.org/10.1586/17474086.2014.958464 (2014).
doi: 10.1586/17474086.2014.958464
pubmed: 25227702
Liu, Y., Bewersdorf, J. P., Stahl, M. & Zeidan, A. M. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: the dawn of a new era? Blood Rev. 34, 67–83 (2019).
doi: 10.1016/j.blre.2018.12.001
pubmed: 30553527
Gill, S. et al. Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells. Blood J. Am. Soc. Hematol. 123, 2343–2354. https://doi.org/10.1182/blood-2013-09-529537 (2014).
doi: 10.1182/blood-2013-09-529537
Liu, Z., Lei, W., Wang, H., Liu, X. & Fu, R. Challenges and strategies associated with CAR-T cell therapy in blood malignancies. Exp. Hematol. Oncol. 13, 22. https://doi.org/10.1186/s40164-024-00490-x (2024).
doi: 10.1186/s40164-024-00490-x
pubmed: 38402232
pmcid: 10893672
Frenay, J. et al. IL-1RAP, a key therapeutic target in cancer. Int. J. Mol. Sci. 23, 14918 (2022). https://www.mdpi.com/1422-0067/23/23/14918#
doi: 10.3390/ijms232314918
pubmed: 36499246
pmcid: 9735758
Järås, M. et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc. Natl. Acad. Sci. 107, 16280–16285. https://doi.org/10.1073/pnas.1004408107 (2010).
doi: 10.1073/pnas.1004408107
pubmed: 20805474
pmcid: 2941341
Warda, W. et al. CML hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor–engineered T cells. Cancer Res. 79, 663–675. https://doi.org/10.1158/0008-5472.CAN-18-1078 (2019).
doi: 10.1158/0008-5472.CAN-18-1078
pubmed: 30514753
Ågerstam, H. et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc. Natl. Acad. Sci. 112, 10786–10791. https://doi.org/10.1073/pnas.1422749112 (2015).
doi: 10.1073/pnas.1422749112
pubmed: 26261316
pmcid: 4553807
Zhao, K. et al. IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients. Int. J. Clin. Exp. Med. 7, 4787 (2014).
pubmed: 25663975
pmcid: 4307422
Trad, R. et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J. Immunother. Cancer 10 (2022).
Zhang, Y. et al. IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells. J. Hematol. Oncol. 17, 67. https://doi.org/10.1186/s13045-024-01586-x (2024).
doi: 10.1186/s13045-024-01586-x
pubmed: 39143574
pmcid: 11325815
Sainson, R. C. et al. ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models. Cancer Res. 84, 2360–2360. https://doi.org/10.1158/1538-7445.AM2024-2360 (2024).
doi: 10.1158/1538-7445.AM2024-2360
Wu, X. et al. Advances in drug delivery systems for the treatment of acute myeloid leukemia. Small. 2403409 https://doi.org/10.1002/smll.202403409 (2024).
Li, F. et al. Recent advances in material technology for leukemia treatments. Adv. Mater., 2313955 (2024).
Sudo, K. et al. Human-derived fusogenic peptides for the intracellular delivery of proteins. J. Control Release. 255, 1–11. https://doi.org/10.1016/j.jconrel.2017.03.398 (2017).
doi: 10.1016/j.jconrel.2017.03.398
pubmed: 28385674
Wadia, J. S., Stan, R. V. & Dowdy, S. F. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10, 310–315. https://doi.org/10.1038/nm996 (2004).
doi: 10.1038/nm996
pubmed: 14770178
Kaplan, I. M., Wadia, J. S. & Dowdy, S. F. Cationic TAT peptide transduction domain enters cells by macropinocytosis. J. Control Release. 102, 247–253. https://doi.org/10.1016/j.jconrel.2004.10.018 (2005).
doi: 10.1016/j.jconrel.2004.10.018
pubmed: 15653149
Nakase, I. et al. Cellular uptake of arginine-rich peptides: roles for macropinocytosis and actin rearrangement. Mol. Ther. 10, 1011–1022. https://doi.org/10.1016/j.ymthe.2004.08.010 (2004).
doi: 10.1016/j.ymthe.2004.08.010
pubmed: 15564133
Lim, J. P. & Gleeson, P. A. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell. Biol. 89, 836–843. https://doi.org/10.1038/icb.2011.20 (2011).
doi: 10.1038/icb.2011.20
pubmed: 21423264
Maxfield, F. R. & Yamashiro, D. J. Endosome acidification and the pathways of receptor-mediated endocytosis. Immunobiol. Proteins pept. IV. 189–198. https://doi.org/10.1007/978-1-4684-5442-0_16 (1987).
Huotari, J. & Helenius, A. Endosome maturation. EMBO j. 30, 3481–3500. https://doi.org/10.1038/emboj.2011.286 (2011).
doi: 10.1038/emboj.2011.286
pubmed: 21878991
pmcid: 3181477
Ahmad, A., Khan, J. M. & Haque, S. Strategies in the design of endosomolytic agents for facilitating endosomal escape in nanoparticles. Biochim. 160, 61–75. https://doi.org/10.1016/j.biochi.2019.02.012 (2019).
doi: 10.1016/j.biochi.2019.02.012
Varkouhi, A. K., Scholte, M., Storm, G. & Haisma, H. J. Endosomal escape pathways for delivery of biologicals. J. Control Release. 151, 220–228. https://doi.org/10.1016/j.jconrel.2010.11.004 (2011).
doi: 10.1016/j.jconrel.2010.11.004
pubmed: 21078351
Lönn, P. et al. Enhancing endosomal escape for intracellular delivery of macromolecular biologic therapeutics. Sci. Rep. 6, 32301. https://doi.org/10.1038/srep32301 (2016).
Suzuki, M., Iwaki, K., Kikuchi, M., Fujiwara, K. & Doi, N. Characterization of the membrane penetration-enhancing peptide S19 derived from human syncytin-1 for the intracellular delivery of TAT-fused proteins. Biochem. Biophys. Res. Commun. 586, 63–67. https://doi.org/10.1016/j.bbrc.2021.11.065 (2022).
doi: 10.1016/j.bbrc.2021.11.065
pubmed: 34826702
Nakamura, M., Fujiwara, K. & Doi, N. Cytoplasmic delivery of siRNA using human-derived membrane penetration-enhancing peptide. J. Nanobiotechnol. 20, 458. https://doi.org/10.1186/s12951-022-01667-4 (2022).
doi: 10.1186/s12951-022-01667-4
Sørensen, H. P., Sperling-Petersen, H. U. & Mortensen, K. K. A favorable solubility partner for the recombinant expression of streptavidin. Protein Expr. Purif. 32, 252–259. https://doi.org/10.1016/j.pep.2003.07.001 (2003).
doi: 10.1016/j.pep.2003.07.001
pubmed: 14965771
Farokhi-Fard, A. et al. Bacterial production and biophysical characterization of a hard-to-fold scFv against myeloid leukemia cell surface marker, IL-1RAP. Mol. Biol. Rep. 50, 1191–1202. https://doi.org/10.1007/s11033-022-07972-3 (2023).
doi: 10.1007/s11033-022-07972-3
pubmed: 36435922
Jain, A. & Cheng, K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J. Controlled Release. 245, 27–40 (2017).
doi: 10.1016/j.jconrel.2016.11.016
Rinne, J. et al. 188. Internalization of novel delivery vector TAT-streptavidin into human cells. Mol. Ther. 13, S73, (2006). https://doi.org/10.1016/j.ymthe.2006.08.212
Kipriyanov, S. M. et al. Affinity enhancement of a recombinant antibody: formation of complexes with multiple valency by a single-chain fv fragment–core streptavidin fusion. Protein Eng. Des. Sel. 9, 203–211. https://doi.org/10.1093/protein/9.2.203 (1996).
doi: 10.1093/protein/9.2.203
López-Andarias, J. et al. Cell-penetrating streptavidin: a general tool for bifunctional delivery with spatiotemporal control, mediated by transport systems such as adaptive benzopolysulfane networks. J. Am. Chem. Soc. 142, 4784–4792. https://doi.org/10.1021/jacs.9b13621 (2020).
doi: 10.1021/jacs.9b13621
pubmed: 32109058
pmcid: 7307903
Jain, A. & Cheng, K. The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis. J. Control Release. 245, 27–40. https://doi.org/10.1016/j.jconrel.2016.11.016 (2017).
doi: 10.1016/j.jconrel.2016.11.016
pubmed: 27865853
Cheal, S. M., Chung, S. K., Vaughn, B. A., Cheung, N. K. V. & Larson, S. M. Pretargeting: a path forward for radioimmunotherapy. J. Nucl. Med. 63, 1302–1315. https://doi.org/10.2967/jnumed.121.262186 (2022).
doi: 10.2967/jnumed.121.262186
pubmed: 36215514
Sun, W., Fletcher, D., van Heeckeren, R. C. & Davis, P. B. Non-covalent ligand conjugation to biotinylated DNA nanoparticles using TAT peptide genetically fused to monovalent streptavidin. J. Drug Target. 20, 678–690. https://doi.org/10.3109/1061186X.2012.712128 (2012).
doi: 10.3109/1061186X.2012.712128
pubmed: 22845840
pmcid: 4143894
Erazo-Oliveras, A., Muthukrishnan, N., Baker, R., Wang, T. Y. & Pellois, J. P. Improving the endosomal escape of cell-penetrating peptides and their cargos: strategies and challenges. Pharm. 5, 1177–1209. https://doi.org/10.3390/ph5111177 (2012).
doi: 10.3390/ph5111177
Boado, R. J. et al. Genetic engineering, expression, and activity of a chimeric monoclonal antibody – avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans. Bioconjug. Chem. 19, 731–739. https://doi.org/10.1021/bc7004076 (2008).
doi: 10.1021/bc7004076
pubmed: 18278853
Zhou, Q. H., Lu, J. Z., Hui, E. K. W., Boado, R. J. & Pardridge, W. M. Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein. Bioconjug. Chem. 22, 1611–1618. https://doi.org/10.1021/bc200174x (2011).
doi: 10.1021/bc200174x
pubmed: 21707084
pmcid: 3157551
Demonte, D., Dundas, C. M. & Park, S. Expression and purification of soluble monomeric streptavidin in Escherichia coli. Appl. Microbiol. Biotechnol. 98, 6285–6295. https://doi.org/10.1007/s00253-014-5682-y (2014).
doi: 10.1007/s00253-014-5682-y
pubmed: 24691867
Trad, R. et al. Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. J. Immunother Cancer. 10 https://doi.org/10.1136%2Fjitc-2021-004222 (2022).
Houtsma, R. et al. CombiFlow: combinatorial AML-specific plasma membrane expression profiles allow longitudinal tracking of clones. Blood Adv. 6, 2129–2143. https://doi.org/10.1182/bloodadvances.2021005018 (2022).
doi: 10.1182/bloodadvances.2021005018
pubmed: 34543390
pmcid: 9006304
Barreyro, L. et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood J. Am. Soc. Hematol. 120, 1290–1298. https://doi.org/10.1182/blood-2012-01-404699 (2012).
doi: 10.1182/blood-2012-01-404699
Kim, J. W. et al. Cancer-associated molecular signature in the tissue samples of patients with cirrhosis. Hepatol. 39, 518–527. https://doi.org/10.1002/hep.20053 (2004).
doi: 10.1002/hep.20053
Zhang, H. F. et al. Proteomic screens for suppressors of anoikis identify IL1RAP as a promising surface target in ewing sarcoma. Cancer Discov. 11, 2884–2903. https://doi.org/10.1158/2159-8290.CD-20-1690 (2021).
doi: 10.1158/2159-8290.CD-20-1690
pubmed: 34021002
pmcid: 8563374
Zhang, Y. et al. Innate immune mediator, Interleukin-1 receptor accessory protein (IL1RAP), is expressed and pro-tumorigenic in pancreatic cancer. J. Hematol. Oncol. 15, 70. https://doi.org/10.1186/s13045-022-01286-4 (2022).
doi: 10.1186/s13045-022-01286-4
pubmed: 35606824
pmcid: 9128118
Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Sci. 321, 1801–1806. https://doi.org/10.1126/science.1164368 (2008).
doi: 10.1126/science.1164368
Li, F., Zhang, W., Wang, M. & Jia, P. IL1RAP regulated by PRPRD promotes gliomas progression via inducing neuronal synapse development and neuron differentiation in vitro. Pathol. Res. Pract. 216, 153141. https://doi.org/10.1016/j.prp.2020.153141 (2020).
doi: 10.1016/j.prp.2020.153141
pubmed: 32829106
Zheng, P. et al. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer. Biomed. Pharmacother. 107, 1064–1073. https://doi.org/10.1016/j.biopha.2018.07.099 (2018).
doi: 10.1016/j.biopha.2018.07.099
pubmed: 30257318
Rydberg Millrud, C. et al. Blockade of IL-1α and IL-1β signaling by the anti-IL1RAP antibody nadunolimab (CAN04) mediates synergistic anti-tumor efficacy with chemotherapy. Cancer Immunol. Immunother. 72, 667–678. https://doi.org/10.1146/annurev.immunol.021908.132612 (2023).
doi: 10.1146/annurev.immunol.021908.132612
pubmed: 36036818
Liu, F. et al. SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis. Oncogene. 37, 2394–2409. https://doi.org/10.1038/s41388-017-0119-6 (2018).
doi: 10.1038/s41388-017-0119-6
pubmed: 29429992
pmcid: 5931977
Lv, Q., Xia, Q., Li, A. & Wang, Z. The potential role of IL1RAP on tumor microenvironment-related inflammatory factors in stomach adenocarcinoma. Technol. Cancer Res. Treat. 20, 1533033821995282. https://doi.org/10.1177/1533033821995282 (2021).
doi: 10.1177/1533033821995282
pubmed: 33602046
pmcid: 7897808
Nakase, I. et al. Interaction of arginine-rich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochem. 46, 492–501. https://doi.org/10.1021/bi0612824 (2007).
doi: 10.1021/bi0612824
Suzuki, T. et al. Possible existence of common internalization mechanisms among arginine-rich peptides. J. Biol. Chem. 277, 2437–2443. https://doi.org/10.1074/jbc.M110017200 (2002).
doi: 10.1074/jbc.M110017200
pubmed: 11711547
Baler, K. et al. Electrostatic unfolding and interactions of albumin driven by pH changes: a molecular dynamics study. J. Phys. Chem. B. 118, 921–930. https://doi.org/10.1021/jp409936v (2014).
doi: 10.1021/jp409936v
pubmed: 24393011
pmcid: 3983335
Salama, M. M., Aborehab, N. M., Mahdy, E., Zayed, N. M., Ezzat, S. M. & A. & Nanotechnology in leukemia: diagnosis, efficient-targeted drug delivery, and clinical trials. Eur. J. Med. Res. 28, 566 (2023).
doi: 10.1186/s40001-023-01539-z
pubmed: 38053150
pmcid: 10696888
Shen, J. et al. Advances of nanoparticles for leukemia treatment. ACS Biomater. Sci. Eng. 6, 6478–6489 (2020).
doi: 10.1021/acsbiomaterials.0c01040
pubmed: 33320613
Kim, Y. H. Heme oxygenase 1-targeted hybrid nanoparticle for chemo-and immuno-combination therapy in acute myelogenous leukemia. (2020). https://doi.org/10.1002/advs.202000487
Ying-ping Jiang, J. Y. T. Holger Karsunky. Antibodies that bind membrane-bound il1rap. (Filing date: 2013-12-20).
Lim, K. H., Huang, H., Pralle, A. & Park, S. Stable, high-affinity streptavidin monomer for protein labeling and monovalent biotin detection. Biotechnol. Bioeng. 110, 57–67. https://doi.org/10.1002/bit.24605 (2013).
doi: 10.1002/bit.24605
pubmed: 22806584
Rahmati, S. et al. Computational engineering of protein L to achieve an optimal affinity chromatography resin for purification of antibody fragments. Anal. Chem. 93, 15253–15261. https://doi.org/10.1021/acs.analchem.1c01871 (2021).
doi: 10.1021/acs.analchem.1c01871
pubmed: 34747593
Rahmati, S. et al. Computational designing of the ligands of protein L affinity chromatography based on molecular docking and molecular dynamics simulations. J. Biomol. Struct. Dyn.. 1–11. https://doi.org/10.1080/07391102.2023.2268219 (2023).
Heo, L., Park, H., Seok, C. & GalaxyRefine Protein structure refinement driven by side-chain repacking. Nucleic Acids Res. 41, W384–W388. https://doi.org/10.1093/nar/gkt458 (2013).
doi: 10.1093/nar/gkt458
pubmed: 23737448
pmcid: 3692086
Wiederstein, M. & Sippl, M. J. ProSA-web: interactive web service for the recognition of errors in three-dimensional structures of proteins. Nucleic Acids Res. 35 https://doi.org/10.1093/nar/gkm290 (2007). W407-W410.
Wallace, A. C., Laskowski, R. A. & Thornton, J. M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng. Des. Select. 8, 127–134 (1995).
doi: 10.1093/protein/8.2.127
Hebditch, M., Carballo-Amador, M. A., Charonis, S., Curtis, R. & Warwicker, J. Protein–Sol: a web tool for predicting protein solubility from sequence. Bioinform. 33, 3098–3100. https://doi.org/10.1093/bioinformatics/btx345 (2017).
doi: 10.1093/bioinformatics/btx345
Nguyen, M. N. et al. AllerCatPro 2.0: a web server for predicting protein allergenicity potential. Nucleic Acids res. 50, W36-W43. https://doi.org/10.1093/nar/gkac446 (2022).
Jouybari, R. M., Sadeghi, A., Khansarinejad, B., Abbasian, S. S. & Abtahi, H. Production of recombinant streptavidin and optimization of refolding conditions for recovery of biological activity. Rep. Biochem. Mol. Biol. 6, 178 (2018).
Won, J. S., Kang, H. W., Nam, P. W. & Choe, M. H. B3 (Fab)-streptavidin tetramer has higher binding avidity than B3 (scFv)-streptavidin tetramer. Bull. Korean Chem. Soc. 30, 1101–1106. https://doi.org/10.5012/bkcs.2009.30.5.1101 (2009).
doi: 10.5012/bkcs.2009.30.5.1101
Sano, T., Smith, C. L. & Cantor, C. R. Expression and purification of recombinant streptavidin-containing chimeric proteins. Recomb Protein Protoc. : Detect. isol. 119–128. https://doi.org/10.1385/0-89603-481-X:119 (1997).
Won, J. S., Kang, H. W., Nam, P. W. & Choe, M. H. B3 (Fab)-streptavidin tetramer has higher binding avidity than B3 (scFv)-streptavidin tetramer. Bull. Korean Chem. Soc. 30, 1101–1106 (2009).
doi: 10.5012/bkcs.2009.30.5.1101
Sørensen, H. P., Sperling-Petersen, H. U. & Mortensen, K. K. Dialysis strategies for protein refolding: preparative streptavidin production. Protein Expr. Purif. 31, 149–154. https://doi.org/10.1016/S1046-5928(03)00133-5 (2003).
doi: 10.1016/S1046-5928(03)00133-5
pubmed: 12963352
Kamiloglu, S., Sari, G., Ozdal, T. & Capanoglu, E. Guidelines for cell viability assays. Food Front. 1, 332–349. https://doi.org/10.1002/fft2.44 (2020).
doi: 10.1002/fft2.44